---
title: IDT Australia vs J-STAR Research, Inc.
slug_a: idtaus-com
slug_b: jstar-research
site: cdmo
review_signal_gate: closed
canonical_path: /compare/idtaus-com/jstar-research
---

# IDT Australia vs J-STAR Research, Inc.

Side-by-side profile data from each company listing on this directory.

## IDT Australia

- Profile: [/companies/idtaus-com](/companies/idtaus-com)

IDT Australia — IDT Australia is a cGMP CDMO delivering end-to-end pharmaceutical development and manufacturing services from active pharmaceutical ingredients to finished dosage forms, with expertise in small molecule APIs, specialty orals, advanced therapies, and integrated regulatory support.

Services: 18. Modalities: 3. Indications: 3. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in services (18).

### Services

- Regulatory Affairs
- Small Molecule Development & Manufacturing
- API Synthesis & Manufacturing
- HPAPI Manufacturing (High-Potency)
- ADC (Antibody-Drug Conjugate) Manufacturing
- ADC Payload & Linker Synthesis
- Sterile Fill-Finish & Aseptic Manufacturing
- Vial Filling
- Lyophilization (Freeze Drying)
- Oral Solid Dosage Manufacturing
- Process Development
- Formulation Development
- Technology Transfer
- CMC Analytical Development
- Quality Control Testing
- Stability Testing & Storage
- Secondary Packaging & Labeling
- CMC Regulatory Submission Support

### Modalities

- Small Molecule
- Antibody-Drug Conjugate (ADC)
- Radiopharmaceutical

### Development capabilities

- Analytical method development
- Formulation development
- ICH stability testing

### Manufacturing capabilities

- Drug Substance (DS)
- Drug Product (DP)
- Liquid Vials
- Lyophilized Vials
- Oral Solid Dose (OSD)
- HPAPI
- DEA licensed

## J-STAR Research, Inc.

- Profile: [/companies/jstar-research](/companies/jstar-research)

J-STAR Research, Inc. — Contract process R&D and cGMP manufacturing for small molecule pharmaceuticals, specializing in high-potent compounds, controlled substances, crystallization development, and analytical services across Phase 1–3 clinical programs.

Services: 10. Modalities: 2. Indications: 0. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in services (10).

### Services

- HPAPI Manufacturing (High-Potency)
- Controlled Substance Manufacturing
- Flow Chemistry & Continuous Manufacturing
- Solid-State Chemistry & Polymorph Screening
- ADC Payload & Linker Synthesis
- Process Development
- Formulation Development
- CMC Analytical Development
- Quality Control Testing
- Stability Testing & Storage

### Modalities

- Small Molecule
- Antibody-Drug Conjugate (ADC)

### Development capabilities

- Analytical method development
- Formulation development
- ICH stability testing
- Solid-state characterization

### Manufacturing capabilities

- Drug Substance (DS)
- Drug Product (DP)
- HPAPI
- DEA licensed
- Flow Chemistry